Aerovant: Phase IIb data

In the double-blind, dose-ranging, U.S. and European Phase IIb AeroTrial trial in 534 patients inadequately controlled with inhaled corticosteroids and long-acting beta-2 adrenergic agonists (LABAs), all 3 doses of inhaled Aerovant missed the primary endpoint of significantly reducing the incidence of asthma exacerbations vs. placebo. Aerovant also missed all secondary endpoints vs. placebo. ...